Payment overview · 2025
General Payments
$2,492.17
163 reported records · 16 companies
Healthcare provider profile · identity verified
Audrey Renee Smith, DO
Allopathic & Osteopathic Physicians|Family Medicine · ASHLAND, KY · NPI 1538514567
Verified facts
What the public records show
CMS Open Payments records show Audrey Renee Smith, DO received $2,492.17 in general payments during 2025 across 163 reported records.
ABBVIE INC. accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Shingrix, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $497.56 | 20.0% | 55 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $471.36 | 18.9% | 26 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $281.42 | 11.3% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $225.84 | 9.1% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $223.35 | 9.0% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $153.24 | 6.2% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $152.84 | 6.1% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $97.31 | 3.9% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $91.26 | 3.7% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $78.81 | 3.2% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $65.55 | 2.6% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.65 | 1.8% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $36.51 | 1.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.81 | 1.2% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $21.40 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.26 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,492.17 | 163 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $261.86 | 16 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $250.29 | 15 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $240.53 | 19 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $223.35 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $209.50 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $196.75 | 14 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $194.43 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $193.98 | 3 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $162.57 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $162.57 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $137.92 | 30 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $119.90 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $109.09 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $104.73 | 9 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $100.31 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $97.31 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $95.29 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $91.26 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $82.31 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $78.81 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $68.70 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $68.70 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $68.70 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $65.55 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $48.51 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $45.41 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $43.65 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.03 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $32.94 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.81 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 133 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 110 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 133 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 11 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 149 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
149 | 36 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
133 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 583 | 142 |
| Omeprazole | Omeprazole | 511 | 139 |
| Atorvastatin Calcium | Atorvastatin Calcium | 500 | 148 |
| Lisinopril | Lisinopril | 488 | 124 |
| Potassium Chloride | Potassium Chloride | 416 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 106 |
| Losartan Potassium | Losartan Potassium | 326 | 83 |
| Montelukast Sodium | Montelukast Sodium | 316 | 86 |
| Furosemide | Furosemide | 278 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 76 |
| Pravastatin Sodium | Pravastatin Sodium | 271 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 265 | 76 |
| Sertraline Hcl | Sertraline Hcl | 255 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 65 |
| Buspirone Hcl | Buspirone Hcl | 220 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 201 | 47 |
| Metformin Hcl | Metformin Hcl | 194 | 53 |
| Gabapentin | Gabapentin | 158 | 50 |
| Synthroid | Levothyroxine Sodium | 149 | 36 |
| Carvedilol | Carvedilol | 147 | 38 |
| Methylprednisolone | Methylprednisolone | 146 | 117 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 142 | 118 |
| Trazodone Hcl | Trazodone Hcl | 139 | 40 |
| Eliquis | Apixaban | 133 | 28 |
| Mounjaro | Tirzepatide | 133 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 130 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 126 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 26 |
| Famotidine | Famotidine | 121 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 33 |
| Metformin Hcl Er | Metformin Hcl | 113 | 29 |
| Jardiance | Empagliflozin | 110 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 107 | 28 |
| Prednisone | Prednisone | 107 | 76 |
| Tramadol Hcl | Tramadol Hcl | 106 | 31 |
| Donepezil Hcl | Donepezil Hcl | 102 | 30 |
| Meloxicam | Meloxicam | 101 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 96 | 29 |
| Simvastatin | Simvastatin | 96 | 27 |
| Allopurinol | Allopurinol | 95 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 89 | 19 |
| Alendronate Sodium | Alendronate Sodium | 86 | 26 |
| Januvia | Sitagliptin Phosphate | 85 | 20 |
| Spironolactone | Spironolactone | 80 | 20 |
| Ozempic | Semaglutide | 76 | 15 |
| Clonazepam | Clonazepam | 75 | 12 |
| Fluconazole | Fluconazole | 75 | 47 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 75 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 22 |
| Ezetimibe | Ezetimibe | 68 | 20 |
| Nystatin | Nystatin | 67 | 31 |
| Celecoxib | Celecoxib | 66 | 22 |
| Alprazolam | Alprazolam | 62 | 17 |
| Glipizide Er | Glipizide | 62 | 16 |
| Lansoprazole | Lansoprazole | 59 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 17 |
| Mirtazapine | Mirtazapine | 52 | 16 |
| Bupropion Xl | Bupropion Hcl | 51 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 12 |
| Nifedipine Er | Nifedipine | 50 | 16 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 48 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 18 |
| Atenolol | Atenolol | 47 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 15 |
| Glimepiride | Glimepiride | 46 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 12 |
| Warfarin Sodium | Warfarin Sodium | 43 | 11 |
| Diclofenac Sodium Er | Diclofenac Sodium | 42 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 14 |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 15 |
| Gemfibrozil | Gemfibrozil | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 37 | 11 |
| Memantine Hcl | Memantine Hcl | 36 | 11 |
| Primidone | Primidone | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Lovastatin | Lovastatin | 35 | 12 |
| Terazosin Hcl | Terazosin Hcl | 35 | suppressed |
| Topiramate | Topiramate | 34 | 11 |
| Estradiol | Estradiol | 33 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 13 |
| Mupirocin | Mupirocin | 31 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 14 |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Ibuprofen | Ibuprofen | 25 | 13 |
| Cephalexin | Cephalexin | 24 | 21 |
| Torsemide | Torsemide | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 13 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Valsartan | Valsartan | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 12 |
| Ibu | Ibuprofen | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,492.17 · 163 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BEVESPI AEROSPHERE, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, Fluad, Flucelvax, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error